Enveda raised $311 million in a Series E to expand its nature-derived AI drug discovery pipeline, with three programs currently in human testing. The startup said ENV-294 and ENV-308 have shown positive early clinical results, while ENV-6949 targets the TL1A pathway in inflammatory bowel disease. The financing also underscores investor appetite for AI-native discovery companies moving from platform validation into later-stage execution. Enveda’s stated approach—using AI to identify biologically active molecules in plants and microbes—frames this round as a scaling and clinic-advancement step. In parallel AI-biotech momentum, Basecamp Research also raised $140 million to advance in vivo cell therapy design using its EDEN foundation model, with Anthropic named as an investor. Taken together, the funding signals continued capital flow to models that can translate discovery outputs into clinical candidates—especially when backed by early human data.